Prenumeration
Genetic Analysis AS (”Genetic Analysis” or ”the Company”) has developed the GA-map®, a platform for diagnostic analysis of microbiomes. The GA-map® platform aims to standardize microbiome diagnostics, which is expected to generate high long-term sales growth with a CAGR of 39% from 2024-2028. Since our previous analysis update, we have raised our justified market cap for Genetic Analysis from approximately NOK 49m to around NOK 77m, considering the reduced financial risk following the capital raises as well as the launch of a consumer test in the Chinese market, which, according to Analyst Group, holds strong potential. However, given the estimated increase in the number of shares following the capital raises, the increase in terms of value per share is more modest. With an applied EV/S multiple of 1.8x on 2027’s estimated sales of NOK 44.5m and a discount rate of 12.4%, a potential present value per share of NOK 1.09 (1.0) is derived in a Base scenario.
Read the equity research report here
Read Analyst Group’s comment on Genetic Analysis and the rights issue here
About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)
This is a press release from Analyst Group regarding the publication of an analysis on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the commentary. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.